Article
Over the past 2 decades, oncology has witnessed unprecedented advances—from molecular diagnostics and immunotherapies to precision medicine and the early integration of machine learning. As these clinical innovations accelerate, attention rightly centers on breakthroughs in diagnosis and treatment. Yet beneath these highly visible advancements lies a growing and far less acknowledged malignancy that quietly threatens patient outcomes, clinician well-being, and the operational integrity of cancer programs: administrative toxicity. We define administrative toxicity as the cumulative burden of nonclinical processes—such as authorization requirements, documentation, coordination demands, and coverage determinations—that create delays, distress, and disruptions in the delivery of timely, evidence-based cancer care.
As Jodi-Ann Burey describes in Authentic, administrative toxicity is not merely bureaucratic friction but a lived experience that exacerbates vulnerabilities and can trigger avoidance, delay, and disengagement from needed care. Her reflections illustrate how layers of paperwork, phone calls, documentation loops, and hostile accommodations generate emotional and material clutter that actively obstruct timely diagnosis and treatment.¹
Clinical toxicity is expected and financial toxicity is now widely recognized. However, administrative toxicity—and its related construct, "logistic toxicity"²—remains underdefined, undertheorized, and insufficiently measured. Although commonly framed as a clinician or system inconvenience, administrative toxicity is a direct, material harm experienced by patients. Delays in care, misaligned incentives, duplicative documentation requirements, opaque payer processes, and fragmented coordination can convert bureaucratic friction into clinical consequences. In oncology—where even short delays may shift prognosis—burdens represent not only inefficiencies but system-generated hazards that endanger timely access to evidence-based care.
Administrative toxicity manifests across multiple domains, including prior authorization, payer communications, coverage appeals, documentation demands, claims adjudication, and fragmented electronic health records (EHRs). These burdens erode clinician capacity, siphon organizational resources, and disproportionately impact rural and under-resourced cancer programs. Within the past 2 decades, we have added language to the cancer care lexicon to define and establish the varying adverse effects of cancer care: financial toxicity, time toxicity, and administrative burdens.³⁻⁵
Given the time-critical nature of oncology, cancer programs must treat administrative toxicity not as an inconvenience, but as an operational and quality-of-care emergency. In this article, we:
Conceptualizing Administrative Toxicity
Administrative toxicity is distinct from financial and time toxicity, though closely related to both through the delays, denials, and coordination failures embedded in health system bureaucracy and utilization management. It encompasses the operational and policy-driven requirements—often justified in the name of cost containment, compliance, or utilization oversight—that can ultimately obstruct rather than facilitate timely, equitable care.⁶ Though designed to promote accountability, these processes frequently produce friction, delay, and distress that erode both the patient experience and clinical efficacy.
Administrative toxicity can be conceptualized across 4 interrelated domains, as shown in the Figure:
Administrative toxicity imposes burdens on patients, caregivers, clinicians, and cancer programs alike. Patients and caregivers lose time, emotional energy, and often trust as they attempt to navigate opaque insurance or social service systems. Clinicians and staff are forced to spend hours on non-value-added tasks, leading to burnout and moral injury.
Recent conceptual models illustrate how administrative burden, time burden, and financial burden intersect, compounding and intensifying inequities in cancer care.⁷ In our framework, administrative toxicity functions as a systemic exposure that depletes both patient capacity and institutional resources, ultimately influencing outcomes, access, and sustainability. Common manifestations of administrative toxicity in oncology include:
In aggregate, these forces undermine the core mission of oncology care—timely, person-centered treatment—by introducing delay, cognitive load, and inefficiency. Like other toxicities in oncology, administrative toxicity has dose-dependent consequences, with the heaviest burden borne by rural and under-resourced cancer programs where staffing, technology, and administrative capacity are most limited.
Delayed Care, Denied Care, Damaged Outcomes
Administrative delays are not rare or peripheral; rather, they are systemic and consequential. Oncology care is inherently time-critical, with many treatments—including adjuvant chemotherapy, radiation, and targeted therapy—being highly time-sensitive. Delays of days or weeks may allow tumor progression, reduce the window of operability, or lower relative survival rates. A national cross-sectional study found that 22% of oncology patients reported being denied or delayed in receiving their recommended cancer care due to prior authorization issues.⁸ Among those who faced delays, nearly three-quarters waited at least 2 weeks.
These delays are more than inconvenient. They are dangerous. A broad review of 25 US studies found prior authorization was associated with disease progression, preventable hospitalizations, prolonged inpatient stays, and lower rates of disease-free survival. Even when approvals are eventually granted (often after exhausting appeals), the damage may already be done.⁹ A national CancerCare survey found that although 95% of requested authorizations were ultimately approved, 40% of patients still experienced treatment delays. Nearly 1 in 3 had diagnostic delays.¹⁰ These are not isolated cases; they reflect a system in dysfunction. Radiation oncologists report seeing this firsthand. In a 2024 survey by the American Society for Radiation Oncology (ASTRO), 92% of respondents said prior authorization caused treatment delays. Nearly a third observed that those delays contributed to emergency department visits, hospitalizations, or even permanent disability. Alarmingly, 7% reported that the delays contributed to patient deaths.¹¹
Distrust, Distress, and Other Consequences of Administrative Toxicity
Beyond clinical harm, administrative toxicity has significant emotional and psychological consequences. Patients frequently describe payer interactions, denials, and repetitive documentation requests as confusing, degrading, and dehumanizing. The cognitive load required to navigate these processes—particularly during active treatment—may intensify distress, weaken engagement in shared decision-making, and impair adherence to medical advice.5,12,13 Patients and their caregivers experience this time and energy depletion when they spend hours on phone calls, appeals, and paperwork to secure care that clinicians have already deemed medically appropriate.14,15 Qualitative analyses capture themes such as "blinded navigation" and "intersecting burdens," illustrating how patients feel lost in a maze of bureaucracy while simultaneously managing cancer-related fatigue, pain, or emotional overwhelm.12,13
Survey data show that 40% of patients rate prior authorization as "bad" and 32% as "horrible." These negative interactions erode trust, not only in insurers (89%) but in the broader health care system (83%).⁸
The consequences of diminished trust are operationally significant. Patients may delay asking clarifying questions, hesitate to challenge denials, or disengage altogether. Administrative hurdles may drive therapy substitutions toward less effective or more toxic regimens, simply because they are easier to authorize. Financial toxicity—often a downstream effect of administrative coverage disputes and delays—can lead to patient non-adherence to therapy, treatment interruptions, or outright abandonment.¹⁵
Disproportionate Harm in Rural and Low-Resource Settings
Administrative toxicity does not fall evenly across the oncology landscape. It amplifies existing disparities and has the most severe consequences in rural clinics and under-resourced communities. Patients who rely on small community oncology programs—many of which operate with limited staffing and administrative infrastructure—are more likely to experience longer delays in prior authorization, reduced access to appeals expertise, and fewer navigation supports.
Empirical evidence consistently demonstrates that younger patients and Black patients report higher administrative burdens and are more likely to delay or skip care altogether due to the complexity or cost of administrative requirements. Patients with limited English proficiency or low health literacy encounter even greater barriers when navigating insurance appeals and paperwork-heavy processes.¹²
These systems were not designed for patients with limited time, resources, or support.
Rural and community oncology clinics face particular vulnerabilities: fewer authorization specialists, limited broadband Internet access to online payer portals, and staffing shortages that make it difficult to absorb the heavy administrative load. These constraints widen equity gaps and ultimately threaten the sustainability of smaller practices that are already under economic strain.¹⁶ For some rural patients, administrative delays may be the tipping point between receiving timely care locally or needing to travel long distances—if travel is even feasible.
Provider Burden, Moral Injury, and Organizational Strain
Administrative toxicity does not affect only patients; it places a substantial and escalating burden on oncology clinicians, support staff, and cancer program operations. Prior authorization alone consumes an average of 13 hours per physician per week—nearly 2 full working days—with documentation, coverage verification, and claims adjudication adding further to that load.¹⁷ These demands erode professional satisfaction, contribute to burnout and moral injury, and divert resources from direct patient care.
In oncology specifically, the impact is even more pronounced. In the ASTRO survey, 94% of radiation oncologists reported that prior authorization exacerbates staff burnout, compounding the same administrative burdens that impair patient outcomes.¹¹ Many cancer programs have had to reassign clinical staff or hire additional personnel solely to manage administrative workflows, diverting resources from quality improvement, survivorship care, or patient education.
In modern oncology programs, large teams of nonclinical staff, such as authorization specialists, financial navigators, and billing coordinators, have become essential. Yet these roles largely exist to manage payer friction, not to enhance clinical care. The opportunity cost is significant: Staff and funds that could be deployed for supportive services, patient education, or research are instead focused on bureaucratic navigation.
This administrative overload contributes not only to burnout but to moral injury—the distress clinicians experience when systemic barriers prevent them from delivering the timely, evidence-based care they know is appropriate. When treatment must be delayed, modified, or rationed due to payer requirements rather than clinical judgment, clinicians face an ethical tension that undermines their sense of professional purpose.¹⁸ Several studies have shown that these conditions degrade patient–clinician relationships, as clinicians spend more time navigating bureaucratic hurdles and less time in conversation, shared decision-making, and holistic care.19,20
The burden is especially acute in rural and small community oncology practices. These programs often lack the administrative depth and technological infrastructure to efficiently manage authorization queues, payer communications, and appeals. Without dedicated authorization specialists or financial navigators, delays lengthen, authorization backlogs accumulate, and already limited staff absorb excessive administrative duties.¹⁶ This dynamic threatens the viability of small cancer programs and, by extension, the stability of oncology access in underserved regions.
EHRs introduce parallel challenges. 2017 ASCO data indicate that 49% of physicians' time is spent on EHR and administrative activities, whereas only 27% of the clinical day is spent with patients.²¹ When clinicians spend nearly twice as much time on systems navigation as on direct care, the clinical mission of oncology becomes increasingly difficult to fulfill. These trends reveal that administrative toxicity functions as an organizational hazard—one that undermines clinician well-being, disrupts workflows, and threatens the sustainability of oncology practices, particularly in rural and resource-limited settings.
Proposed Strategies to Mitigate and Reduce Administrative Toxicity
The evidence is clear: Administrative barriers in oncology are not neutral safeguards but structural failures that impede timely care, widen disparities, and erode trust in the health care system. For cancer programs seeking to deliver equitable, guideline-concordant care, reducing administrative toxicity is not optional—it is essential to operational performance, clinical well-being, and patient outcomes.
Because administrative toxicity arises from policy, payer practices, health system workflows, and patient-facing processes, meaningful reform requires multilevel, multistakeholder coordination. While some changes require systemic reform, many others can be implemented immediately within oncology programs to buffer patients and staff from administrative burden.
Challenges, Trade-Offs, and Future Directions
Efforts to reduce administrative toxicity must contend with practical, structural, and policy-level obstacles. While momentum is growing—particularly as some payers begin scaling back prior authorization requirements for selected diagnostic services22,23 reforms must be designed carefully to avoid unintended consequences. Emerging automation tools may streamline certain processes, but algorithmic decision-making can also entrench inequities or reduce clinical nuance if implemented without appropriate safeguards.24,25 Key considerations include:
Future Directions
Key priorities for the field include:
Conclusion
Administrative toxicity is not a peripheral inconvenience; it is a substantive and growing threat to the safety, equity, and effectiveness of cancer care. In a field where timeliness is critical, delays and denials generated by administrative processes cause iatrogenic harm that undermines the very advances oncology has worked hard to achieve. Its consequences are measurable: disrupted treatment pathways, compromised outcomes, magnified disparities, clinician burnout, and operational strain across cancer programs.
As the oncology community continues to invest in scientific and therapeutic innovation, equal attention must be directed toward confronting the bureaucratic systems that impede the delivery of those advances. Reducing administrative toxicity requires intentional, coordinated action across payers, policymakers, health care systems, professional societies, and patient advocacy partners.
Every reduction in administrative burden is a meaningful gain—faster access to treatment, improved patient experience, reduced inequities, and a more resilient oncology workforce. These benefits make reducing administrative toxicity not only an operational priority but also an ethical imperative for cancer care systems that are committed to delivering timely, person-centered, and equitable care. The goal is straightforward: Restore time, clarity, and dignity to patients and capacity and agency to the clinicians who care for them.
Frantz M. Berthaud, MPH, FACHE, is senior vice president of Oncology Services at University Medical Center of El Paso in El Paso, Texas. Christabel K. Cheung, PhD, MSW, is an associate professor at the University of Maryland School of Social Work in Baltimore, Maryland.
References
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
